Search

Your search keyword '"Tauras, James M."' showing total 21 results
Start Over Author "Tauras, James M."
21 results on '"Tauras, James M."'

2. Global Longitudinal Strain Is Associated with Mortality in Patients with Multiple Myeloma

Author

Cui, Zhu, primary, Castagna, Francesco, additional, Hanif, Waqas, additional, Apple, Samuel J., additional, Zhang, Lili, additional, Tauras, James M., additional, Braunschweig, Ira, additional, Kaur, Gurbakhash, additional, Janakiram, Murali, additional, Wang, Yanhua, additional, Fang, Yanan, additional, Diaz, Juan C., additional, Hoyos, Carolina, additional, Marin, Jorge, additional, Pellikka, Patricia A., additional, Romero, Jorge E., additional, Garcia, Mario J., additional, Verma, Amit K., additional, Shah, Nishi, additional, and Slipczuk, Leandro, additional

Published
2023
Full Text
View/download PDF

11. Redox regulation of cell signalling

Author

Lander, Harry M., Milbank, Aaron J., Tauras, James M., Hajjar, David P., Hempstead, Barbara L., Schwartz, Gregory D., Kraemer, Rosemary T., Mirza, Urooj A., Chait, Brian T., Burk, Sharon Campbell, and Quilliam, Lawrence A.

Published
1996

13. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure

Author

Felker, G. Michael, primary, Mentz, Robert J., additional, Cole, Robert T., additional, Adams, Kirkwood F., additional, Egnaczyk, Gregory F., additional, Fiuzat, Mona, additional, Patel, Chetan B., additional, Echols, Melvin, additional, Khouri, Michel G., additional, Tauras, James M., additional, Gupta, Divya, additional, Monds, Pamela, additional, Roberts, Rhonda, additional, and O’Connor, Christopher M., additional

Published
2017
Full Text
View/download PDF

14. The Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure Study: A Randomized, Double blind, Placebo-Controlled Trial in Acute Heart Failure

Author

Mentz, Robert J., primary, Felker, G. Michael, additional, Cole, Robert, additional, Adams, Kirkwood F., additional, Egnaczyk, Gregory, additional, Fiuzat, Mona, additional, Patel, Chetan B., additional, Echols, Melvin, additional, Khouri, Michel, additional, Tauras, James M., additional, Gupta, Divya, additional, Monds, Pamela, additional, Roberts, Rhonda, additional, and O'Connor, Christopher M., additional

Published
2016
Full Text
View/download PDF

20. Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras-dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress*

Author

Lander, Harry M., Tauras, James M., Ogiste, Jason S., Hori, Osamu, Moss, Rebecca A., and Schmidt, Ann Marie

Abstract

Advanced glycation end products (AGEs) exert their cellular effects on cells by interacting with specific cellular receptors, the best characterized of which is the receptor for AGE (RAGE). The transductional processes by which RAGE ligation transmits signals to the nuclei of cells is unknown and was investigated. AGE-albumin, a prototypic ligand, activated p21 rasin rat pulmonary artery smooth muscle cells that express RAGE, whereas nonglycated albumin was without effect. MAP kinase activity was enhanced at concentrations of AGE-albumin, which activated p21 rasand NF-κB. Depletion of intracellular glutathione rendered cells more sensitive to AGE-mediated activation of this signaling pathway. In contrast, signaling was blocked by preventing p21 rasfrom associating with the plasma membrane or mutating Cys118on p21 rasto Ser. Signaling was receptor-dependent, because it was prevented by blocking access to RAGE with either anti-RAGE IgG or by excess soluble RAGE. These data suggest that RAGE-mediated induction of cellular oxidant stress triggers a cascade of intracellular signals involving p21 rasand MAP kinase, culminating in transcription factor activation. The molecular mechanism that triggers this pathway likely involves oxidant modification and activation of p21 ras.

Published
1997
Full Text
View/download PDF

21. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.

Author

Felker, G Michael, Mentz, Robert J, Cole, Robert, Adams, Kirkwood F, Egnaczyk, Gregory F, Fiuzat, Mona, Patel, Chetan B, Echols, Melvin, Khouri, Michel G, Tauras, James M, Gupta, Divya, Monds, Pamela, Roberts, Rhonda, O'Connor, Christopher M, and Cole, Robert T

Subjects
*HETEROCYCLIC compounds, *COMPARATIVE studies, *DYSPNEA, *HEART failure, *KIDNEY function tests, *LONGITUDINAL method, *RESEARCH methodology, *MEDICAL cooperation, *RESEARCH, *STATISTICAL sampling, *VASOPRESSIN, *EVALUATION research, *RANDOMIZED controlled trials, *BLIND experiment, *CHEMICAL inhibitors
Abstract

Background: The oral vasopressin-2 receptor antagonist tolvaptan causes aquaresis in patients with volume overload, potentially facilitating decongestion and improving the clinical course of patients with acute heart failure (AHF).Objectives: The TACTICS-HF (Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure) study was conducted to address the acute use of tolvaptan to improve congestion in AHF.Methods: The TACTICS-HF study randomized patients (n = 257) within 24 h of AHF presentation in a prospective, double blind, placebo-controlled trial. Patients were eligible regardless of ejection fraction, and were randomized to either 30 mg of tolvaptan or placebo given at 0, 24, and 48 h, with a fixed-dose furosemide regimen as background therapy. The primary endpoint was the proportion of patients considered responders at 24 h. Secondary endpoints included symptom improvement, changes in renal function, and clinical events.Results: Dyspnea relief by Likert scale was similar between groups at 8 h (25% moderately or markedly improved with tolvaptan vs. 28% placebo; p = 0.59) and at 24 h (50% tolvaptan vs. 47% placebo; p = 0.80). Need for rescue therapy was also similar at 24 h (21% tolvaptan, 18% placebo; p = 0.57). The proportion defined as responders at 24 h (primary study endpoint) was 16% for tolvaptan and 20% for placebo (p = 0.32). Tolvaptan resulted in greater weight loss and net fluid loss compared with placebo, but tolvaptan-treated patients were more likely to experience worsening renal function during treatment. There were no differences in in-hospital or post-discharge clinical outcomes.Conclusions: In patients hospitalized with AHF, dyspnea, and congestion, the addition of tolvaptan to a standardized furosemide regimen did not improve the number of responders at 24 h, despite greater weight loss and fluid loss. (Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure [TACTICS-HF]; NCT01644331). [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results